"Visit the UCLA Health website for coronavirus updates."

During the past decade, California Liver Institute conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 3 clinical trials were completed, i.e. on average, 150% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 1 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "California Liver Institute" are "Chronic Hepatitis C" (1 trials), "Decompensated Cirrhosis" (1 trials), "Hepatic Cirrhosis" (1 trials), "Hepatic Fibrosis" (1 trials) and "Hepatitis C Virus" (1 trials). Many other conditions were trialed in "California Liver Institute" in a lesser frequency.

Most popular intervention types in "California Liver Institute" are "Drug" (4 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (3 trials), "Daclatasvir" (1 trials), "Emricasan (25 mg)" (1 trials), "Emricasan (5 mg)" (1 trials) and "IDN-6556" (1 trials). Other intervention names were less common.

The vast majority of trials in "California Liver Institute" are 5 trials for "All" genders.

Currently, there are NaN active trials in "California Liver Institute". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 4 completed trials in California Liver Institute, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in California Liver Institute, 0 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".